Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 595-603

  Xiang, Zixiu ^a   Thompson, Analisa D ^a   Jones, Carrie K ^a   Lindsley, Craig W ^a   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ANTAGONIST; N [3 OXO 3 [4 (4 PYRIDINYL) 1 PIPERAZINYL]PROPYL] 2,1,3 BENZOTHIADIAZOLE 4 SULFONAMIDE; SCOPOLAMINE; UNCLASSIFIED DRUG; VU 0255035;

AKINESIA; ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN FUNCTION; CATALEPSY; CHOLINERGIC ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EVOKED CORTICAL RESPONSE; GABAERGIC TRANSMISSION; LATENT PERIOD; MALE; MOTOR NERVE CONDUCTION; MOUSE; NERVE CELL EXCITABILITY; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION; TREATMENT DURATION;

ANIMALS; BASAL GANGLIA; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION;

EID: 84857249092     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187856     Document Type: Article

References (38)

1. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, and Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6:51-58. (Pubitemid 36026332)
2. Barbeau A (1962) The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 87:802-807.
3. Bergman H, Wichmann T, and DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438.
4. Beurrier C, Congar P, Bioulac B, and Hammond C (1999) Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. J Neurosci 19:599-609. (Pubitemid 29036011)
5. Bevan MD and Bolam JP (1995) Cholinergic, GABAergic, and glutamate-enriched inputs from the mesopontine tegmentum to the subthalamic nucleus in the rat. J Neurosci 15:7105-7120.
6. Chen JJ and Swope DM (2007) Pharmacotherapy for Parkinson's disease. Pharmacotherapy 27:161S-173S. (Pubitemid 350234306)
7. Collingridge GL and Davies J (1981) The influence of striatal stimulation and putative neurotransmitters on identified neurones in the rat substantia nigra. Brain Res 212:345-359. (Pubitemid 11152826)
8. Cross AJ and Waddington JL (1980) [3H] Quinuclidinyl benzylate and [3H] GABA receptor binding in rat substantia nigra after 6-hydroxy-dopamine lesions. Neurosci Lett 17:271-275. (Pubitemid 10122795)
9. Davie CA (2008) A review of Parkinson's disease. Br Med Bull 86:109-127.
10. De Montis GM, Olianas MC, Serra G, Tagliamonte A, and Scheel-Krüger J (1979) Evidence that a nigral gabaergic- cholinergic balance controls posture. Eur J Pharmacol 53:181-190. (Pubitemid 9201107)
11. DeLong MR and Wichmann T (2007) Circuits and circuit disorders of the basal ganglia. Arch Neurol 64:20-24. (Pubitemid 46072419)
12. Drachman DA and Leavitt J (1974) Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30:113-121.
13. Feger J, Hammond C, and Rouzaire-Dubois B (1979) Pharmacological properties of acetylcholine-induced excitation of subthalamic nucleus neurones. Br J Pharmacol 65:511-515. (Pubitemid 9116981)
14. Felder CC, Bymaster FP, Ward J, and DeLapp N (2000) Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 43:4333-4353. (Pubitemid 32046857)
15. Flores G, Hernandez S, Rosales MG, Sierra A, Martines-Fong D, Flores-Hernandez J, and Aceves J (1996) M3 muscarinic receptors mediate cholinergic excitation of the spontaneous activity of subthalamic neurons in the rat. Neurosci Lett 203:203-206. (Pubitemid 26040210)
16. Galarraga E, Hernández-López S, Reyes A, Miranda I, Bermudez-Rattoni F, Vilchis C, and Bargas J (1999) Cholinergic modulation of neostriatal output: a functional antagonism between different types of muscarinic receptors. J Neurosci 19:3629-3638. (Pubitemid 29203141)
17. Giachetti A, Giraldo E, Ladinsky H, and Montagna E (1986) Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol 89:83-90. (Pubitemid 16031207)
18. Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13:244-254.
19. Hernández-López S, Flores G, Rosales MG, Sierra A, Martínez-Fong D, and Aceves J (1996) Muscarinic antagonists microinjected into the subthalamic nucleus decrease muscular rigidity in reserpinized rats. Neurosci Lett 213:157-160. (Pubitemid 26264368)
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
21. Johnson KA, Conn PJ, and Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 8:475-491.
22. Katzenschlager R, Sampaio C, Costa J, and Lees A (2003) Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev CD003735.
23. Lavoie B and Parent A (1994a) Pedunculopontine nucleus in the squirrel monkey: cholinergic and glutamatergic projections to the substantia nigra. J Comp Neurol 344:232-241. (Pubitemid 24151191)
24. Lavoie B and Parent A (1994b) Pedunculopontine nucleus in the squirrel monkey: projections to the basal ganglia as revealed by anterograde tract-tracing methods. J Comp Neurol 344:210-231. (Pubitemid 24151190)
25. Lester DB, Rogers TD, and Blaha CD (2010) Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:137-162.
26. Miyakawa T, Yamada M, Duttaroy A, and Wess J (2001) Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 21:5239-5250. (Pubitemid 32622949)
27. Pisani A, Bernardi G, Ding J, and Surmeier DJ (2007) Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30:545-553. (Pubitemid 47513239)
28. Richards CD, Shiroyama T, and Kitai ST (1997) Electrophysiological and immunocytochemical characterization of GABA and dopamine neurons in the substantia nigra of the rat. Neuroscience 80:545-557. (Pubitemid 27334602)
29. Sheffler DJ, Williams R, Bridges TM, Xiang Z, Kane AS, Byun NE, Jadhav S, Mock MM, Zheng F, Lewis LM, et al. (2009) A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol 76:356-368.
30. Shen KZ and Johnson SW (2000) Presynaptic dopamine D2 and muscarine M3 receptors inhibit excitatory and inhibitory transmission to rat subthalamic neurones in vitro. J Physiol 525:331-341.
31. Shen W, Hamilton SE, Nathanson NM, and Surmeier DJ (2005) Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci 25:7449-7458. (Pubitemid 41129818)
32. Shen W, Tian X, Day M, Ulrich S, Tkatch T, Nathanson NM, and Surmeier DJ (2007) Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat Neurosci 10:1458-1466. (Pubitemid 350014670)
33. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, et al. (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29:14271-14286.
34. Starr PA, Vitek JL, and Bakay RA (1998) Deep brain stimulation for movement disorders. Neurosurg Clin N Am 9:381-402.
35. Tien XY and Wallace LJ (1985) Trihexyphenidyl-further evidence for muscarinic receptor subclassification. Biochem Pharmacol 34:588-590.
36. Turski L, Havemann U, and Kuschinsky K (1984) Role of muscarinic cholinergic mechanisms in the substantia nigra pars reticulata in mediating muscular rigidity in rats. Naunyn Schmiedebergs Arch Pharmacol 327:14-17. (Pubitemid 14061584)
37. van der Kooy D, Hattori T, Shannak K, and Hornykiewicz O (1981) The pallidosubthalamic projection in rat: anatomical and biochemical studies. Brain Res 204:253-268. (Pubitemid 11205699)
38. Wilson CJ (2004) Basal ganglia, in The Synaptic Organization of the Brain (Shepherd GM ed) pp 361-413, Oxford University Press, New York.